Roche to acquire Carmot Therapeutics for US$ 2.7 billion
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Subscribe To Our Newsletter & Stay Updated